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Kawalan Dislipidemia dan Tindakbalas Mudarat Drug Statin di 
Kalangan Pesakit di Klinik Jantung Hospital Pulau Pinang, Malaysia 
ABSTRAK 
Ramai pesakit di Malaysia menggunakan statin untuk pencegahan masalah 
kardiovaskular dan kematian. Walau bagaimanapun, data tempatan tentang 
keberkesanan dan keselamatan terapi statin adalah sangat  kurang. Oleh itu, objektif 
kajian ini adalah untuk menilai kawalan dislipidemia dan kesan mudarat drug (ADR) 
statin ke atas pesakit Malaysia. Kajian ini telah dijalankan di Klinik Kardiak, Hospital 
Pulau Pinang, Malaysia. Penilaian kawalan dislipidemia adalah berdasarkan kepada 
cadangan oleh National Cholesterol Education Program (NCEP), USA. Kesan 
mudarat drug  minor adalah berasaskan   persepsi pesakit terhadap kesan tidak diingin 
yang dialami semasa terapi statin.  Manakala, ADR serius adalah berdasarkan kepada 
maklumat makmal (enzim hati, ujian fungsi ginjal dan nilai “creatinine kinase”). 
Program statistik SPSS versi 12,  dengan ANOVA, Chi Kuasa Dua, Ujian Ketepatan 
Fisher, Ujian t Bebas dan  Ujian Pasangan t telah digunakan mengikut kesesuaian 
dengan nilai p<0.05 adalah signifikan. Terdapat 500 pesakit terlibat, lebih separuh 
daripada mereka adalah lelaki (70%). Kebanyakan pesakit ini adalah berbangsa Cina 
(37.6%), diikuti oleh bangsa Melayu (34.4%), bangsa India (26.6%) dan lain-lain 
(1.4%). Purata umur mereka adalah 59.8 ± 10.3 tahun (28-91 tahun). Penilaian 
kawalan dislipidemia  menunjukkan 44% dan 41% pesakit-pesakit ini  masing-masing 
mempunyai LDL dan selain-LDL yang terkawal. Penurunan dislipidemia daripada 
setiap lawatan susulan ke klinik dibandingkan dengan lawatan pertama adalah berbeza, 
bergantung kepada jenis-jenis lemak (LDL, selain-HDL, TG, TC, dan HDL). Purata  
penurunan dislipidemia dibahagikan jumlah lawatan bagi LDL adalah 26 ± 2%, 
selain-HDL, 22.15  ± 2%, TC, 17.7 ± 1.2 %, dan TG, 27.25 ± 2.65%. Purata 
 xxv
peningkatan untuk HDL dibahagikan dengan jumlah lawatan adalah 10.58 ± 7.33 %. 
Simptom ADR minor yang paling sering (59.4 %) dan teruk adalah kelesuan. Insiden 
risiko hepatoksisiti (>1.5 “upper limit normal”) masing-masing adalah 3.25% dan 
3.82% berdasarkan kepada enzim hati, ALT dan AST. Risiko toksisiti otot (>1.5 
“upper limit normal”) adalah 3.2%. Peratus pengurangan fungsi renal  (CRCL) 
sebanyak  25%  adalah 3%, sementara peratus pengurangan CRCL sebanyak 50% 
adalah 0.65%. Setengah faktor-faktor penyumbang seperti bangsa, jantina, jenis 
dislipidemia, ketagihan alkohol, jenis statin yang digunakan, dos, kombinasi terapi 
antilemak, tempoh masa terapi statin (lebih dari 5 tahun) dan ubat-ubat lain yang 
diambil bersama menyumbang didalam pengawalan dislipidemia dan ADR. 
Kesimpulannya didapati kurang separuh daripada pesakit-pesakit yang terkawal 
dislipidemianya dalam kajian ini. Lebih sedikit separuh daripada mereka mengalami 
ADR minor, manakala hanya peratusan yang kecil sahaja yang mengalami ADR 
serius. Dos rendah lovastatin (20mg) didapati mencukupi untuk mengawal 
dislipidemia dalam kebanyakkan pesakit. Dos rendah  dan tempoh masa terapi statin 
kurang dari 5 tahun di dapati mengurangkan risiko ADR.   
 xxvi
Dyslipidemia Control and Adverse Drug Reactions of Statins Among   
Patients at Cardiac Clinic of Penang Hospital, Malaysia   
ABSTRACT  
Many Malaysian patients use statin for prevention from cardiovascular problems and 
mortality. However, local data on the effectiveness and safety of statin therapy are 
very scanty. Thus, the objective of this study is to assess the dyslipidemia control and 
adverse drug reactions (ADRs) of statins for Malaysian patients. The study was 
carried out at Cardiac Clinic, Penang Hospital, Malaysia. The assessment of the 
dyslipidemia control was based on National Cholesterol Education Program (NCEP), 
USA recommendations. Minor ADRs, were based on the patients’ perceptions on 
undesired effects that they had during statin therapy. While serious ADRs were based 
on laboratory information (liver enzymes, renal function test, and creatinine kinase 
values). Statistical program SPSS version 12, with ANOVA, Chi Square, Fisher 
Exact Test, Independent t Test and Paired t Test were used when appropriate with p 
value <0.05 as significant. There were 500 patients involved, more than half of them 
were male (70%). Many of these patients were Chinese (37.6%) followed by Malay 
(34.4%), Indian (26.6%) and others (1.4%). Their mean age was 59.8 ± 10.3 years 
(28-91years). Dyslipidemia control assessment showed 44% and 41% of these 
patients had their LDL and non-HDL under control, respectively. Lipids reduction 
from each clinic visit compared to the first visit were varied depending on the types 
of lipids (LDL, non-HDL, TG, TC and HDL). The mean lipid reduction per total 
visits were LDL 26 ± 2%, non-HDL, 22.15 ± 2%, TC, 17.7 ± 1.2%, and TG, 27.25 ± 
2.65%, respectively. The mean increment for HDL divided by total visits was 10.58 
± 7.33%. The most common (59.4%) and severe symptom of minor ADRs was 
fatigue. The incidence risk of hepatotoxicity (>1.5 upper limit normal) were 3.25% 
 xxvii
and 3.82% based on liver enzymes, ALT and AST, respectively. The risk of muscle 
toxicity (>1.5 upper limit normal) was 3.2%. The percentage of reduction in renal 
function (CRCL) by 25% was 3%, while the percentage of reduction by 50% was 
0.65%. Some of the contributing factors such as race, gender, type of dyslipidemia, 
alcohol consumption, type of statins used, dose, combination of antidyslipidemic 
therapy, duration of statin use (more than 5 years) and concurrent medications used 
contributed towards dyslipidemia control and ADRs. In conclusion, it was found less 
than half of the patients in this study had dyslipidemia under control. Slightly more 
than half (59.4%) had minor ADRs, while only a small percentage developed serious 
ADRs. Low dose of lovastatin (20mg) was found sufficient to achieve dyslipidemia 
control in the majority of these patients.  Low dose and duration of statin therapy of 
less than 5 years decreased the risk of ADRs. 
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CHAPTER 1 
INTRODUCTION  
1. Background  
1.1 Dyslipidemia    
        Dyslipidemia is defined as an abnormality in one or more type of lipids in the 
blood (NCEP, 2001), Dyslipidemia is a strong predictor and pathogenic factor for 
cardiovascular diseases (CVD) and contributes to the development of coronary graft 
atherosclerosis occlusion (Campeau et al, 1984). There is a real relationship between 
lowering the blood cholesterol level and the incidence of CVD. For example, if the 
cholesterol level is decreased by 1% then the incidence of CVD decreases by 1%, 
and, over a five-year period, there is an approximate reduction in CVD of 30%. 
(Neaton et al, 1992; Grundy et al, 2004; 4S study, 1994).  
 
1.2 Types and etiology of dyslipidemia 
      There are two types of dyslipidemia, primary and secondary dyslipidemia. The 
type of dyslipidemia depends on the etiology and the diseases that lead to the 
increase in the lipid level.  
 
1.2.1 Primary dyslipidemia 
       Primary dyslipidemia is typically due to either a single or multiple genetic 
alterations that may lead to either overproduction or a defective mechanism in the 
clearance of cholesterol, triglycerides (TG), very low density lipoprotein (VLDL), 
low-density lipoprotein (LDL) or an excess clearance of high-density lipoprotein 
(HDL). According to the Fredrickson classification, primary dyslipidemia can be 
subdivided into different types depending on the level of elevation of lipids and 
lipoproteins (Friedewald et al, 1972; American Diabetes Association, 2006; NCEP, 
2001), as shown in Table 1.1.       
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Table 1.1 Types and properties of primary dyslipidemia (Friedewald et al, 1972) 
Type Elevated lipoproteins Elevated lipids 
I  Primary hyperlipoproteinemia or Familial 
hyperchylomicronemia 
Chylomicron  TGs 
IIa Polygenic hypercholesterolemia or 
Familial hypercholesterolemia 
LDL Cholesterol 
IIb  Combined hyperlipidemia LDL and VLDL  TGs and cholesterol 
III   Familial dysbetalipoproteinemia VLDL (VLDL:TG ratio > 0.3) 
and  Chylomicron  
TGs and cholesterol 
IV Endogenous hyperlipidemia VLDL  TGs 
V  Familial hypertriglyceridemia Chylomicron and VLDL TGs and cholesterol 
TG= Triglyceride, HDL=High density lipoprotein, LDL=low density lipoprotein, VLDL= very low density lipoprotein 
 
1.2.2 Secondary dyslipidemia  
        Secondary dyslipidemia may occur at an advanced age, especially when an 
elevation in lipids levels is initiated and accompanied by several diseases, including 
diabetes, hypothyroidism, hepatic diseases, renal insufficiency, pregnancy and  
systemic lupus or chronic usage of drugs (such as estrogen, thiazide, beta blockers 
and others) and alcohol use. These above-mentioned contributing factors may be 
more prevalent in developed countries because of their different lifestyle (NCEP, 
2001; Stone et al, 2008), as shown in Table 1.2. 
Table 1.2 Types and properties of secondary dyslipidemia (Stone et al, 2008) 
Disorder Cholesterol TG HDL LDL VLDL Chylomicron 
Other 
tests 
Renal failure Unchanged Increased Decreased Unchanged Increased Unchanged SCr 
Nephrotic 
syndrome Increased Unchanged Unchanged Increased 
Unchanged Unchanged  
Hypothyroidism Increased Increased Unchanged Increased Unchanged Increased TSH 
Type 2 diabetes Increased Increased Decreased Increased Increased Increased Glucose 
Obstructive liver 
disease Increased Unchanged Unchanged Increased Unchanged Unchanged 
Liver 
function 
Ethanol use Unchanged Increased Unchanged Unchanged Increased Unchanged  
Pregnancy Increased Increased٭ Unchanged Increased Increased Unchanged  
Systemic lupus Unchanged Increased Unchanged Unchanged Unchanged Increased  
Drug 
use 
Diuretic 
B-BK 
Estrogen 
Cyclosporin 
Increased 
Unchanged 
Unchanged 
Increased 
Unchanged 
Increased 
Increased 
Unchanged 
Unchanged 
Decreased 
Unchanged 
Unchanged 
Increased 
Unchanged 
Unchanged 
Increased 
Unchanged 
Increased 
Increased 
Unchanged 
Unchanged 
Unchanged 
Unchanged 
Unchanged 
 
 ٭ increased only in third trimester, SCr = Serium creatinine, TSH = Thyroid stimulating hormon 
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1.3. Dyslipidemia therapy targets   
       All the adult treatment panel (ATP) reports from the National Cholesterol 
Education Program (NCEP) in US found a strong relationship between the LDL 
levels and coronary artery diseases, myocardial infarction (MI), strokes, and other 
CVDs. LDL is considered to be the major risk factor among the different types of 
lipids. Another target is non-HDL, which represents all the types of lipoproteins 
except for HDL (NCEP, 2001; Ballantyne et al, 2001). Both HDL and TG have a 
significant relationship with cardiovascular diseases; in which a 1% decrease in the 
level of HDL correlates with a 2-3% increase in the risk of cardiovascular diseases 
(Gordon et al, 1989; American Diabetes Association, 2002). Thus, it is possible to 
consider both HDL and TG as independent risk factors (Austin et al, 1998; Assmann 
et al, 1998; Gordon et al, 1989) and lipid level monitoring that is based on both 
factors is necessary to give satisfactory results. The HDL level is not the ideal goal 
for therapy, since some studies have proven that when the LDL level is lower, there 
is a significantly decrease in the incidence of cardiovascular attacks despite a low 
HDL level (HPS, 2002; Downs et al, 1998). The HDL value may also be affected by 
some drugs. Nicotinic acid and fibrates may increase the HDL level in some patients, 
but not in all patients, since some patients experience a rise in the level as an adverse 
reaction to these drugs (Grundy et al, 2004). Interestingly, the TG value is easily 
influenced by laboratory variability, smoking and alcohol. Therefore, to avoid an 
incorrect assessment of atherogenicity, the patient must fast for 24 hours so that the 
TG atherogenicity will only be present in the TG-rich lipoproteins, especially in 
cases of hypertriglyceridemia (3rd Clinical Practice Guideline on management of 
dyslipidemia, Malaysia, 2003)  
 
     It is easy to identify dyslipidemia by determining the lipid profile and the amount 
of LDL using the Friedewald equation, such that the VLDL is equal to TG/2.2 (when 
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the TG amount is more than 4.5 mmol/L, the equation is invalid).                        
Therefore, the VLDL can be calculated directly from equation 1.1 (Friedewald et al, 
1972).  The non-HDL levels can be calculated by subtracting the HDL level from the 
total cholesterol, which represents all the types of lipoproteins except for HDL 
(equation 1.2).  
LDL (mmol/l) = TC – HDL-C +TG/2.2 …... (1.1) (adapted from Bernard et al, 2002)   
non-HDL = TC – HDL ………..(1.2)   (adapted from Koda-Kmble, 2005)   
 
   
1.4. Dyslipidemia control  
     The control of dyslipidemia is based on the established recommended goals for a 
particular type of lipid profile. 
 
 1.4.1. Categorization of dyslipidemia assessment      
      Depending on the lipids profile, NCEP has classified the recommendation goals 
into low, optimal, desirable, borderline, high and very high, which allows for the 
evaluation for each patient's case (NCEP, 2001). 
Table 1.3 Type of dyslipidemia and assessment categorization (NCEP, 2001)  
lipoproteins Level (mg/dl) Level (mmol/l) Categories  
< 200 < 5.2  Desirable 
200–239   5.2-6.2  Borderline high TC 
≥ 240    > 6.2  High 
< 100   < 2.6  Optimal 
100–129 2.6-3.36  Near optimal/above optimal 
130–159 3.37-4.11  Borderline high 
160–189 4.12-4.91  High 
LDL 
≥ 190      > 4.92  Very high 
< 40  <1.05  Low* HDL 
≥ 60   >1.6  High** 
< 150 <1.7  Desirable 
150–199  1.7-2.3  Borderline high 
200–499 2.31-5.6  High 
TG 
≥ 500     >5.7  Very high 
Note :** HDL > 1.6 is a negative risk factor  
*  HDL < 1.05 is a positive risk factor 
 5
 1.4.2 Established recommended goals 
       
     The recommendations of the NCEP for dyslipidemia control are aimed at 
decreasing or preventing cardiovascular disease attacks. In coronary heart disease 
(CHD) or in equivalent diseases, the target lipid levels are less than 100 mg/dl (2.6 
mmol/l), which is called secondary prevention (NCEP, 2002). Patients with clinical 
CHD and the equivalent diseases have the following characteristics: 
 
1.  Clinical CHD: myocardial ischemia (angina), MI, coronary angioplasty, 
and/or stent placement, coronary bypass graft and prior unstable angina.  
2. Carotid artery disease: stroke history, transient ischemic attack history, 
carotid stenosis > 50%.  
3. Peripheral arterial disease : claudiation,  ankle :brachial index (ABI)  > 0.9  
4. Abdominal aortic aneurysm. 
5. Diabetes mellitus. 
       If the patient does not have any of the above coronary heart diseases or 
equivalents, then he or she must be considered for primary prevention. This 
prevention is influenced by total cholesterol and HDL, age, gender (Wilson, 1998), 
hypertension (Stamler et al, 1993; van den Hoogen et al, 2000), family history of 
CHD (Barrett–Connor and Khaw, 1984), smoking (LaCroix et al, 1991), etc. All of these 
are considered as risk factors for cardiovascular diseases. 
  
       In an effort to prevent cardiovascular diseases, NCEP target some goals (Grundy 
et al, 2004; NCEP, 2001), which are based on the two main lipid factors, LDL and 
non-HDL. 
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1.4.2. (a) Low density lipoprotein (LDL) goals  
1- Patients with coronary heart disease (CHD) and CHD equivalents, including 
diabetes (representing the secondary prevention): LDL < 100 mg/dl (<2.6 
mmol/l) 
2- Patients with multiple risk factors ≥ 2, e.g., smoking, hypertension, family history 
of CHD, etc.  : LDL <130 mg/dl (<3.4 mmol/l) 
3- Patients  with zero to one risk factor and non-CHD: LDL < 160 mg/dl ( <4.16 
mmol/l)   
The second and third goals represent the primary prevention as referred to in Table 
1.4 
 
1.4.2. (b) Non-high density lipoprotein (non-HDL) goals 
1- Patients with coronary heart disease (CHD) and CHD risk equivalents: < 130 
mg/dl (< 3.4 mmol/l)  
2- Patients with multiple risks factors ≥ 2: < 160 mg/dl (< 4.16 mmol/l) 
3- Patients with zero to one risk factor and non-CHD: < 190 mg/dl (< 4.94 mmol/l) 
The goal for non-HDL  
Table 1.4 Targets of dyslipidemia control according to the NCEP reports (NCEP, 
2001) 
LDL goals non-HDL goals 
Prevention 
mg/dl mmol/l mg/dl mmol/l 
Primary <130 <3.4 < 160 < 4.16 
Secondary <100 <2.6 <130 <3.4 
 
      Since there is definite relationship between the lowering of the blood cholesterol 
level and the incidence of cardiovascular diseases, such that a 1% decrease in the 
cholesterol levels decreases the incidence of cardiovascular diseases by 1% (Neaton 
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et al, 1992). According to the epidemiology data in previous studies (Law et al, 1994) 
and NCEP ATP III publication reports, secondary prevention is very important for the 
patients who are suffering from cardiovascular diseases. This is because dyslipidemia 
has a strong relationship, especially with LDL, and has a log linear relationship with 
cardiovascular diseases. The goal recommended for LDL is less than 100 mg/dl. This 
is the level that is referred to as the beginning of coronary heart diseases (Sacks et al, 
1996; LIPID, 1998; 4S, 1994) and this value is also considered to be the minimum 
point that is required to increase the incidence of cardiac attacks. HPS (Heart 
Protection Study) and PROVE-IT trial studies advise individuals to reduce their LDL 
to less than 100 mg/dl to achieve a more pronounced reduction or prevention of 
atherosclerotic lesions (Nissen et al 2004). This is because the HPS study found 
about a 20%-30% and the PROVE-IT study found a 16% reduction in the risks of 
cardiovascular diseases after reaching this goal (Chris and Harvey, 2004). 
 
    For primary prevention, the NCEP recommended that the goal must be less than 
129 mg/dl to reduce the risk of cardiovascular diseases by 30%-40% (Pearson et al, 
2003; NCEP, 2001). 
 
       The use of less effective lowering agents can lead to difficulties in controlling 
the lipid levels, which will lead to an increase in the dose or the need for a 
combination therapy in an effort to achieve the recommended goals (EUROASPIRE 
II Study Group, 2001). 
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1.5. Statins  
      There are many drugs that are used for the treatment of dyslipidemia, including 
the statins. Statins, which are inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG 
CoA) reductase, are considered as one of the most important drugs and the drug of 
choice for reducing an abnormal cholesterol level. Statins are normally used to 
decrease the risk of congestive heart death and non fatal MI, revascularization 
procedures, strokes and other cardiovascular mortality (NCEP, 2001, Grundy et al, 
1997; Vaughan and Gotto, 2004). This is because it can reduce the level of LDL and 
triglycerides, as well as increase the level of HDL (NCEP, 2001). 
 
1.5.1. Mechanism of action         
      Statins have the ability to catalyze the conversion of hydroxymethyl glutaryl-
Coenzyme A (HMGCoA) to mevalonate leading to prevention of cholesterol 
synthesis (Goldstein and Brown, 1990) (Figure1).                                             
                                                   3- hydroxyl-3-methylglutaryl-CoA 
                                Statins  
                                                                   Mevalonate  
 
                                                          Isopentyl-pyrophosphate  
 
                                Dolichole             Farnesyl pyrophosphate            Ubiquinone  
 
                                                                       Squalene 
         
                                                                    Cholesterol   
       
                                       Bile lipoprotein        steroid      hormones   
Figure 1.1 Statin effect on the cholesterol synthesis (Rosanoff, 2004) 
      The secondary mechanism is accomplished by reducing or inhibiting the hepatic 
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synthesis of apolipoprotein B100 and then decreasing the secretion of triglyceride-
lipoprotein (Ginsberg at al, 1987; Grundy et al, 1997) and also through an inhibition 
of the isoperinoid compound that is produced from mevalonate, which exhibits 
pleiotropic properties (Liao, 2002; Corsini et al, 1999). The inhibition of cholesterol 
synthesis causes a stimulation of the sterol regulatory element binding proteins 
(SREBPs).  SREBPs are factors that have the ability to activate a signaling cascade 
that is responsible for the regulation of the LDL-receptor gene expression. After 
these factors are activated, they begin to cross the nuclear membrane where they can 
bind to the sterol response element leading to the regulation of the LDL-receptors in 
the hepatocellular membrane. An increase in the receptors expression causes an 
increase in the cellular uptake of LDL, which leads to a decreased blood circulating 
LDL (William, 2007). Accumulation of mevalonate will lead to an increase in HDL, 
which leads to the inhibition of the cholesterol ester transfer protein (Rosenson and 
Tangney, 1998).  
 
     Accumulation of LDL and VLDL particles in the intimal space leads to the 
development of an atherosclerotic plaque, which contains a lipid core, thin fibrous 
cap and macrophage cells covering the lesions (Vogel et al, 1997). A statin drug 
changes the size of the lesions from big to small and it also softens a hard lesion so 
that it is less easily ruptured. The pleiotropic effects of statins improve the 
endothelial dilatation function and inhibit cell migration and proliferation (Nissen et 
al, 2004; Liao, 2002; Shishehboret al, 2003; Treasure et al, 1995; Baller et al, 1999; 
O'Driscoll et al, 1997). A reduction in the cholesterol level also means there is a 
decrease in the inflammation that normally accompanies atherosclerosis. This 
process involves the activity of monocytes, which have the ability to engulf LDL 
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particles, cause ruptures and release other mediators (cytokines, chemokines, and 
growth factors release). Inhibiting this process by statins will also lead to a decreased 
formation of clots (Libby et al, 2002; Libby, 2001, Henderson et al, 1999; Ridker, 
1998). 
 
1.5.2. Types of Statins        
       Statin drugs include atorvastatin, simvastatin, rosuvastatin, lovastatin, 
pravastatin, fluvastatin and cerivastatin (the last statin was withdrawn from the 
market). Lovastatin was the first discovered as a naturally-occurring substance from 
fungi in 1987, and simvastatin was produced from a semisynthetic derivative of 
lovastatin in 1991. The other types, including fluvastatin, cerivastatin, rosuvastatin 
and atorvastatin, are synthetic enantiomer types (McTaggart et al, 2001; Blumenthal, 
2000). 
 
1.5.3. Pharmacokinetics: 
        The statins differ in terms of their physiochemical properties. Some of them are 
lipophilic, while others are hydrophilic. Some statins have metabolites and some are 
not metabolized. Both simvastatin and lovastatin are prodrugs that are converted in 
the liver so that the lacton ring is opened. While in the other above-mentioned types, 
the ring is already opened (Istvan and Deisenhofer, 2001). Their pharmacokinetic 
properties also differ in terms of their absorption, maximum concentration, 
maximum time, metabolism, protein binding, excretion and bioavailability (Jones 
et.al, 1998; Corsini et al, 2002). The differences in the pharmacokinetics lead to 
differences in the activity and the adverse reactions (Peter, 2003). 
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Table 1.5 Pharmacokinetics of statins (Corsini et al, 2005) 
Parameter Atorvastatin Simvastatin Lovastatin Rosuvastatin Pravastatin Fluvastatin
Absorption % 30 60-80 35 20 34 98 
Tmax (h) 2-3 1.3-2.4 2-4 3 0.9-1.6 0.5-1 
Cmax (ng/ml) 27-66 10-34 10-20 37 45-55 448 
Bioavailability% 12-14 5 5 20 17-18 19-29 
Lipophilicity Yes Yes Yes No No No 
Protein binding% 80-98 94-98 >95 88 43-55 >95 
Metabolism CYP3A4 CYP3A4 CYP3A4 
CYP2C9, 
2C19 (minor) 
Sulfation CYP2C9 
Metabolites Active Active Active 
Active 
(minor) 
Inactive Inactive 
Transporter 
protein substrate 
Yes Yes Yes Yes Yes/No No 
T1/2 (h) 14-30 2-3 2.9-4 19-20.8 1.3-2.8 0.5-2.3 
Urinary excretion 
% 
2 13 10 10 20 6 
Fecal excretion % 70 58-60 83 90 70-71 90 
 
1.5.4. Dosage forms (Jones et al, 1998) 
Simvastatin:   Tablets 5, 10, 20, 40 or 80 mg 
Rosuvastatin: Tablets 5, 10, 20, 40 mg 
Pravastatin:    Tablets 10, 20, 40 mg 
Lovastatin:     Tablets 10, 20, 40 mg 
Fluvastatin:    Tablets 20, 40 mg (capsules); 80 (XL tablets) 
Atorvastatin:  Tablets 10, 20, 40, 80 mg 
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1.5.5. Daily dose    
        The doses are given here as the defined daily dose and they are supported by 
many studies (Jones et al, 1998; Moon, 2006; Andrews et al, 2001; Jones et al, 2003). 
The normal daily dose of statin is represented in Table 1.6 
 
Table 1.6 Statins dosage regimen 
Statin type Dosage regimen 
Atorvastatin 10-40 mg QD and the maximum dose is 80 mg QD at any time  
Simvastatin  20-40 mg Q pm and the maximum dose is 80 mg Q pm with food  
Fluvastatin  20-40 mg Q at bed time and the maximum dose is 40 mg BID or 80 mg 
XL QD 
Lovastatin  20-40 mg with dinner and the maximum dose is 40 mg BID 
Pravastatin  10-40 mg QD and the maximum dose is 40 mg QD 
Rosuvastatin 10-20 mg QD and the maximum dose is 40 mg QD 
QD = once daily   BID= twice daily    
 
1.5.6. Other antihyperlipidemics     
        To reach the goal of treatment, sometimes there is a need to give combination 
therapies with another antihyperlipidemic, such as niacin, ezetimibe, resin, fibrates 
and fish oil. 
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1.5.7. Statins use prevalence 
          Of all the approved antihyperlipidemics, statins are the most frequently used. It 
has been reported that statin use ranges from 62.5% to 91.7% of dyslipidemic 
patients. Additionally, it has been reported that the rate of statins use by cardiac 
patients is between 0.5% to 6.7% (Avorn et al, 1998). In Malaysia, about 90% of 
coronary heart patients use statins (National Cardiovascular Disease Malaysia, 2006). 
 
         There is an increasing trend in statins use since 2003 especially in European 
countries. Ireland and Norway are two countries will a high rate of statins use, while 
Italy is the least-frequent user of statins. It has been reported that the increment of 
statins usage are between 274% and 56% (from 2000 to 2003) for Ireland and 
France, respectively. Some countries prefer to use lovastatin and simvastatin, while 
the other countries prefer rosuvastatin, atorvastatin or simvastatin. Regardless, the 
median of the rate of usage increase in Europe is 25.6% per year from the period 
1999 to 2003 (Walley et al, 2004). 
     
           In the UK, it has been found that most patients who use statins are older than 
35 years old and that 56% of the users are men. The most frequently-used type is 
simvastatin 20 mg (DeWilde et al, 2003). In Canada, about 90% of the utilized lipid 
lowering agents were statins at 2000. While in the US, at least one third of all 
patients use statins (NCEP, 2002). About 60% of statins users were patients older 
than 60 years old in Canada (Farahani et al, 2005) and statins users have increased 
about (1.28% - 6.59%) from the 1996 to 2004. The age of the population who uses 
statins has increased with age range. It has been reported that 0.1% - 0.56% of the 
users were between the ages of 20-45, 1.82%-7.45% of 45-65, 4.25%-20.92% of 65-
85, and 0.45%-8.11% were older than 85 year. While the most common type of statin 
 14
used in US is atorvastatin followed by simvastatin, pravastatin, fluvastatin, lovastatin 
and rosuvastatin. Cerivastatin use has declined since 2003, because of the adverse 
drug reactions problems. The most common diseases in which statins were used are 
ischemic heart disease (35.17%), diabetes (30.02%), peripheral vascular disease 
(3.5%), cerbrovascular disease (7.36%) and atherosclerosis (3.91%) for total number 
of patients in Colombia, US from 1999-2004 (Colette et al, 2007). The rate of usage 
in male patient is 2.62%, which is slightly more than women (2.49%), (Savoie et al, 
2002). In New Zealand, simvastatin was used for the first time in 1986 (Chris and 
Harvey, 2006). Due to the beneficial effects of statins in lowering cholesterol and the 
incidence of cardiovascular diseases, clinicians have encouraged the use of statins 
(French et al, 1990). In Australia, about 85% of the cardiovascular patients used 
atorvastatin and simvastatin from 1992–2003 (Oberg, 1999). 
  
1.5.8. Clinical benefits of statins 
          For the last 50 years, many US patients have suffered from coronary artery 
diseases and in 2002, about 500,000 patients died as a result of cardiovascular 
diseases, like ischemic heart disease (IHD), atherosclerosis, cerbrovascular disease 
or peripheral vascular disease (PVD) (American Heart Association, 2005). Statins 
can be used in both primary and secondary prevention (Wood et al, 1998; NCEP, 
2001). The major benefits of statins for the secondary prevention patients are more 
significant than for the primary prevention patients; there is more need for statins in 
the secondary than in primary dyslipidemia (NICE, 2005; Wilt et al, 2004). Thus, 
most cardiovascular patients use statins. However, the chronic use of statins may 
cause several problems. Patients who do not benefit from statins use should avoid 
this drug to prevent the adverse drug reactions and unnecessary cost. (Svoie, 2002). 
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        These drugs have significantly decreased the incidence of cardiac attacks, 
especially those related to heart failure, and have improved the survivor state of 
mortality cases. It has been reported that there is a direct impact on diastolic heart 
failure with an observed beneficial effect of statins in left ventricle hypertrophy 
patients, since it also exerts antihypertensive effects (Borghi, 2002; Glorioso et al, 
1999) and arterial distensibility (Ferrier et al, 2002). It also improves the endothelial 
function that prevents atherosclerosis (Corti et al, 2002). The prevention effect of 
hypertrophy on the left ventricle (O’Rourke, 2001; Kass et al, 2004), and the 
increased distensibility will reduce mortality and MI cases. Other benefits of statins 
are the anti-inflammatory and antioxidant (Davignon, 2004) effects, which inhibit the 
inflammatory effect and myocardial stress that is caused by an increase in oxygen 
free radicals, which may affect heart failure development (Givertz and Colucci, 
1998). Statins have been documented to prevent strokes, vascular diseases, and 
coronary heart diseases as well as decrease the mortality, morbidity and death 
associated with dyslipidemia (Byington et al, 2001; Sirol et al, 2001). These benefits 
have also been presented in many other studies (Castelli et al, 1991; Levy et al, 1990; 
4S, 1994; WOSCOPS Study Group, 1998). With regard to renal system, statins 
participate to improve kidney function and the GFR (Bays et al, 2005).  
 
      Many previous studies showed a difference in clinical benefits depending on type 
of statin used. This difference are  due to the pharmacokinetic and type of the statin 
used. Based on the Frederickson classifications, all types of statins are indicated for 
type I patients, it is preferred that type IIa and type IIb patients use any of the statins 
except lovastatin, type III patients should preferentially use atorvastatin, pravastatin 
and simvastatin, and type IV patients have been indicated to use all the types of 
statins except fluvastatin and lovastatin (Amin, 2004). Rosuvastatin is considered to 
have more of an effect on the reduction of LDL and an improvement of the lipid 
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profile of patients (McKenney et al, 2003). Atorvastatin is considered to be the most 
active statin because of its anti-inflammatory (Taylor et al, 2002; Wiklund et al, 
2002) and antioxidant effects. These effects are due to the active metabolites that are 
found with atorvastatin more than other types of statins (Shishehbor et al, 2003). 
Simvastatin significantly reduces the mortality associated with coronary heart disease 
(Therapeutics Initiative committee, 1999), while pravastatin significantly reduces the 
incidence of MI in men (Shepherd and Wenger, 1995). Many studies have proven that 
there is a great benefit and effect of statins use in the reduction of cardiovascular 
events. 
 
        The 4S study is considered to be the first study to show that simvastatin has the 
ability to reduce the cholesterol level and then reduce the incidence of cardiovascular 
diseases (Scandinavian Simvastatin Survival Study Group, 1994). The HPS (heart 
protection study) was carried out on 1,000,000 patients in the UK ranging in age 
from 40 to 80 years old who had a high risk of cardiovascular diseases. After 
simvastatin use, a 24% reduction in cardiovascular events and a 27% reduction in 
strokes and a significant reduction (13%) in mortality were observed. The rates of 
coronary death were decreased by 27%, major cardiovascular events were reduced 
by 24%, nonfatal MI were decreased by 25% and there was a 7-10% decrease in the 
risk of diabetes (Serruys et al, 2002; Heart protection study, 2002). The Lescol 
Intervention Prevention (LIP) study found that in patients ranging in age from 18 to 
80 years old, fluvastatin use reduced the risk of cardiovascular events by about 22% 
and the risk of diabetes by 47% (Serruys et al, 2002). The AVERT study proved that 
use of atorvastatin at 80 mg for 1.5 years has the ability to decrease (13%) the 
revascularization procedure that is needed for ischemic patients (Pitt et al, 1999). The 
ASCOT-LLA study, which used atorvastatin at 10 mg for 3.3 years, observed a 36% 
reduction in both non fatal MI and fatal coronary heart diseases, a 27% reduction in 
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risk of stroke and a 29% reduction in risk for total coronary events (Sever et al, 
2003). The CARDS study, which used atorvastatin at 10 mg for 4 years for primary 
prevention patients, found a 37% reduction in cardiovascular events, a 36% reduction 
in acute coronary events, a 31% reduction in the risk of coronary revascularization, a 
48% reduction in the risk of strokes and a 27% reduction in the rate of death 
(Colhoun et al, 2002). The CARE study, which used pravastatin at 40 mg in patients 
with secondary prevention for 5 years, found that there was a 24% decrease in the 
risk of death from CHD or nonfatal MI, a 23% reduction in the risk of nonfatal MI 
and a 31% reduction in the risk of stroke (Sacks et al, 1996). The LIPID study, which 
used pravastatin at 40 mg for 6.1 years, found that there was a 24% reduction in the 
risk of death from CHD, a 25% reduction in death (due to cardiovascular diseases), a 
22% reduction in the risk of death due to CHD or nonfatal MI , a 29% reduction in 
the MI risk and a 19% reduction in the risk of stroke (The Long-term Intervention 
with Pravastatin in Ischemic Disease, 1998). The PROSPER study, which used 
pravastatin at 40 mg that was randomized for 3.2 years, found that there was a 15% 
reduction in risks of death from CHD, nonfatal MI, fatal or non fatal strokes, and a 
24% reduction in the risk of CHD death.(Shepherd et al, 2002). The PACT study, 
which used pravastatin at 20-40 mg, found that there was a reduction in deaths and 
acute cardiovascular events by 6.4%. (Thompson et al, 2004). The PREVEND–IT 
study, which used pravastatin at 40 mg for 4 years, found that there was a 13% 
reduction in the risk of cardiovascular diseases (Asselbergs et al, 2004). The IDEAL 
study, which used atorvastatin (80 mg) and simvastatin (20-40 mg) during the follow 
up of patients who had a MI, found that there was a reduction in the cardiovascular 
risk after 1 year by 21%, while after 2 years there was a 14% reduction and after 5 
years, there was a 34% reduction (Pedersen et al, 2006). 
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1.6. Adverse drug reactions 
           According to the World Health Organization (WHO), an adverse drug reaction 
is defined as any response in which there is a noxious and unintended effect that 
occurs at the normal doses used in man for prophylaxis, diagnosis and therapy of 
disease (Bruce Hawkins, 1995). According to the adverse reactions dictionary, the 
intensity of the adverse event’s severity can be categorized into mild, moderate and 
severe (Connie et al, 2003). 
 
1.6.1. Mechanism of adverse drug reactions of Statins 
       Inhibition of cholesterol synthesis prevents the formation of all of the precursors 
in the cholesterol synthesis pathway and in this process, there are two important 
compounds whose synthesis is inhibited. The inhibition of these two compounds 
leads to adverse drug reactions (ADRs). The operation of their functions are 
explained below. Inhibiting synthesis of these compounds would indirectly affect 
their normal function (Figure 1.1): 
1) Ubiquinone or Co-Enzyme Q10 plays an important role in mitochondria to 
produce ATP, cell membrane activity, formation of collagen and elastin fibers, 
nerve conduction (Goldstein and Brown, 1990; Ely JTA and Krone, 2000). 
2) Dolichole plays a role in glycoprotein manufacture. 
 
       Reducing lipid compounds prevents the production of many important 
compounds, such as bile, hormones, lipoprotein and cytokines (which consists of 
glycoprotein modulators of cellular functions, including interferon, interleukins and 
growth stimulating factors) (Kwak et al, 2000). Lipid reducing compounds also 
suppress helper T-cells and interferon, which stimulate macrophages (Nissen et al, 
2005, Hakamada et al, 2003). Additionally, they suppress IL-6, IL-8 and tumor 
necrosis factor (TNF). (Ikeda and Shimada, 1999; Rezaie et al, 1999; Libby, 2003). 
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The reduction in the plasmatic and intracellular levels of cholesterol may reduce the 
cholesterol membrane wall leading to physical changes and a decrease in cell 
proliferation. Such changes could affect the function of the Na/K pump with 
irreversible damage to the cell. (Ucar, 2000) 
 
1.6.2. Adverse drug reactions (ADRs) of statins 
        Many adverse reactions have been reported with statins use. These ADRs are 
categorized into two categories, minor and serious ADRs. 
 
1.6.2 (a) Minor Adverse drug reactions 
       The minor ADRs include abdominal cramps, diarrhea or constipation, flatulence, 
dyspepsia, back pain, muscle pain, dizziness, chest pain, headache, pharyngitis, flu 
syndrome, nausea and vomiting, sleep disturbances, sexual dysfunction, fatigue, a 
sense of detachment, shortness of breath, vision problems, changes in body 
temperature and blood sugar, dry skin, rashes, blood pressure changes, nausea, upset 
stomach, bleeding, limbs tingling (during sleep), dry cough and phlegm, (Fallon, 
2003; Shepherd et al, 2001; Amin,, 2004; AHFS, 2007).  
 
        Muscle damage is usually accompanied by an increase in serum creatine kinase 
(CK). This enzyme is mainly produced by skeletal muscle and myocardium (Baker 
and Tarnopolsky, 2001). Myalgia is one of the most common muscle disorders that 
may be caused by statins. It is characterized by diffuse muscle pain, tenderness, 
cramps and/or muscle weakness. The symptoms of myalgia are common complaints 
by patients who are on statin therapy (Thompson et al, 2003). The symptoms are 
associated with an increase the CK value. It was found that 2-7% of the patients who 
used statins had an increased CK value. These symptoms are also considered to be 
early symptoms of polyneuropathy, myopathy, or extrapyramidal disorders if they are 
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not treated (Shetty et al, 1998). 
 
1.6.3. Serious adverse drug reactions 
       The serious adverse reactions of statins include myositis, myopathy, 
rhabdomyolysis, polyneuropathy, cancer, liver disease and renal toxicity. These 
serious ADRs rarely occur during statin therapy.  
  
1.6.3(a) Myositis: Muscle symptoms with or without increased CK levels, which are 
characterized by muscle weakness, and a biopsy indicates muscle damage with 
muscle fiber necrosis and inflammatory cell infiltration (Ucar et al, 2000), and the 
incidence is reported to be about 0.1-0.5% of patients who use statins (Pasternak et 
al, 2002) 
 
1.6.3(b) Myopathy: The symptoms are defined as muscle pain, tenderness and /or 
muscle weakness, accompanied by an abnormal elevation in CK. (Ucar et al, 2000). 
The symptoms occur in 0.04-0.2% of the patients who are on statins (Hamilton, 
2003; Pasternak et al, 2002; Maron et al, 2000)   
 
1.6.3(c) Rhabdomyolysis: It is an acute muscle damage in which all the cell 
contents, such as myoglobin, enzymes and electrolytes are released into the 
circulation. The myoglobin and the intracellular components are toxic, especially for 
the kidney. When the urine pH is less than 5.6, myoglobin is converted to ferriheme, 
which is considered a toxin. The precipitation of this product may cause an 
obstruction of the renal tubules and lead to renal vasoconstriction The CK can rise 
between 10 and more than 100 fold above the baseline or upper limit normal (ULN) 
(Lewin et al, 2002). These symptoms occur in 0.05% of the statin patients. They are 
accompanied by severe muscle pain, stiffness, weakness, fever, malaise and dark 
urine (Thompson et al, 2003) and may suffer from renal failure (Hayward et al,2006). 
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1.6.3(d) Polyneuropathy: Known as peripheral neuropathy (irreversible damage), 
which is characterized by weakness, tingling sensations in the limbs, hand and foot 
pain and walking difficulty. These symptoms only occur in patients that use statins 
for 2 or more years (Gaist et al, 2002). 
 
1.6.3(e) Cancer: May occur with use for longer durations. It has been found that skin 
cancer is associated with the use of statins in 243 patients (Sacks et al, 1996; Heart 
Protection Study, 2002). It has also been found that there is a significant increase in 
the risk of breast cancer in women who have had CHD and are treated with 
pravastatin (Pfeffer et al, 2002). 
 
1.6.3(f) Liver diseases: Statins can cause liver diseases. They induce hepatotoxicity 
that mimics the symptoms of any type of hepatobiliary disease (from acute and 
chronic) (Kinnman, 2001). An abnormality in the liver function will start if both liver 
enzymes (ALT and AST) increase by more than 1.5 ULN (Pfeffer et al, 2002). The 
clinical effect of statins is associated with an elevation in the liver transaminase 
levels by more than 3 ULN. These effects have been found in about 300 cases per 
100,000 cases either due to statin drug interactions, comorbidities or a high dose of 
statin (Maron et al, 2000). ALT and AST may increase with the use of statin at a rate 
of more than 1% with the lower and intermediate doses of statin. This rate may 
increase to between 2% to 3% in the patients who are taking the 80 mg dose of statin 
for an average duration of 3 years (Cohen et al, 2006). According to the 2006 report 
from the Alabama Medicaid Agency of Pharmac therapeutic committee meeting, an 
elevation in liver enzymes begin after 12 weeks of statin therapy (McEvoy,2004). 
 
1.6.3(g) Renal toxicity: It is rare, but may occur due to proteinurea, if a high dose of 
statins is used (Alsheikh-Ali et al, 2005; Hayward et al, 2006).  
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1.7. Contributing factors in dyslipidemia control and adverse drug reactions 
        There are many contributing factors that influence the dyslipidemia control and 
ADRs, such as statin types, dose, combination therapy, age, gender, race, alcohol use, 
smoking and duration of therapy. 
   
 1.7.1. Statin types  
         The pharmacokinetic properties (Table 1.5) of statin play a role in dyslipidemia 
control and the adverse drug reactions severity.. Fluvastatin and rosuvastatin have 
lower adverse effects on the CNS, such as headache, dizziness and asthenia (Plosker 
and Wagstaff, 1996; Campbell et al, 2005). Lipophilic statins are metabolized to 
more hydrophilic compounds for excretion, while the hydrophilic statins are excreted 
unchanged, which therefore have a lower drug interactions incidence (Hamelin and 
Turgeon, 1998). Protein binding may be one of the contributing factors for drug 
interactions. The statin types that have a high protein binding (>95%) are more prone 
to interactions by another protein binding agent, which leads to an increase in free 
active drug (Bottorf and Hansten, 2000). The statins (simvastatin, lovastatin and 
atorvastatin) that are metabolized by CYP3A4 are considered to be more toxic to 
muscle cells. More than half of the reported cases of muscle pain were related to 
simvastatin use than other types of statins (Thompson et al, 2003; Ballantyne et al, 
2003). While pravastatin and fluvastatin are not metabolized by the same liver 
enzyme, there is no competition between the metabolic enzymes and therefore their 
concentration will be lower. Since statins as many other drugs are metabolized by 
cytochrome enzymes, a drug-drug interaction can lead to an increase in the plasma 
level of statin (Muscari et al, 2002; NCEP, 2001). Therefore, an adverse drug-drug 
interaction may cause a significant increase in CK and lead to myalgia, myopathy, 
and rhabdomyolysis (Rosenberg et al, 1995; Veerkamp et al, 1996). Some drug-drug 
 23
interactions that can cause rhabdomyolysis due to an increase in the concentration of 
statins in the blood include itraconazole (Segaert et al, 1996), erythromycin (Herman, 
1999), cyclosporin (Meier et al, 1995), and diltiazem (Bottorf and Hansten, 1999). 
The above-mentioned drugs are considered to be moderate CYP3A4 inhibitors when 
used with lovastatin and pravastatin. These drugs may also cause a drug interaction 
that may lead to the prolonging of the actions of statins because of the increase in 
their Cmax (for example, the lovastatin Cmax increases from 6 ng/ml to 26.9 ng/ml) 
(Spach et al, 1991). The incidence of these adverse drug-drug interactions is about 
300 cases per 100,000 cases. The patients have an elevation in the ALT and AST of 
more than 3 ULN when the dose is fixed and unrelated to a reduction in the LDL 
level (Bays, 2006; Law and Rudnicka, 2006). An increased pharmacokinetic rate 
could be contributed by statin interactions or comorbidities or a high statin dose 
(James, 2006). Thousands of New Zealand patients have suffered from a loss of 
dyslipidemia control because their medications were frequently changed from 
atorvastatin to pravastatin or simvastatin (Chris and Harvey, 2006). PHARMAC 
found that fluvastatin is the weakest type of statin in controlling lipid levels among 
all the types, because there is no mortality prevention or improvement of the patients' 
clinical states. Therefore, fluvastatin is not recommended in patients with secondary 
prevention (Chris and Harvey, 2006). Atorvastatin is more frequently used in 
European countries and is considered to be the best and strongest type of statin when 
compared to equivalent strengths of the other statins (Illingworth et al, 1994; Athyros 
et al, 2004; Schwartz et al, 2002; Sever et al, 2003). 
 
    The incidence of ADRs (both minor and serious adverse reactions) for pravastatin 
is 69% followed by simvastatin (63%), rosuvastatin (55%) and atorvastatin (46%) 
(Alsheikh-Ali et al, 2005). Studies have proven that there is no significant difference 
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among the statins in terms of their safety or ADRs (Pasternak et al, 2002). 
Cerivastatin was withdrawn from the market, because according to the WHO 
database, it was associated with 52 cases of death (Wooltorton, 2001; Weber, 2001). 
There were 546 reports of cases of rhabdomyolysis resulting from statin use, which 
were more frequently related to cerivastatin than other types of statins. While the 
FDA received 6498 cases of cerivastatin use that was associated with 
rhabdomyolysis, some of these cases were fatal rhabdomyolysis (Furberg and Pitt, 
2001). The incidence of rhabdomyolysis for cerivastatin is 3.16 per million, followed 
by lovastatin at 0.19 per million, simvastatin at 0.12 per million, pravastatin at 0.04 
per million, atorvastatin at 0.04 per million, and fluvastatin at 0 per million. Statins 
can also cause liver injury and proteinuria (EMEA, 2002), the incidence of these 
ADRs also depends on the type of statin used, such that for atorvastatin the incidence 
is 0.7% and for rosuvastatin 0.4%. Rosuvastatin causes a minimal effect on liver 
injury (1.9%). 
 
      The incidence of myalgia was higher with fluvastatin (5%) and atorvastatin 
(3.2%) compared to the other types of statins, but the incidence of myalgia is 1.2% 
for simvastatin and 2.6% for lovastatin. The incidence of myopathy is the highest 
with rosuvastatin (0.1%) and pravastatin (0.1%), followed by lovastatin (0.08%) and 
atorvastatin (0%) (Davidson, 2005). The rate of muscle disorders is not significantly 
different among the types of statins (Gotto, 2003). In the UK the EXCEL study, 
which included a large number of patients who used lovastatin, found that cases of 
myopathy ranged from 0.1% to 0.2% of the study population, while pravastatin and 
simvastatin had incidences of myopathy from 0.01% to 0.4%. Cerivastatin users 
experienced myopathy in about 1.55% of the study population, which was the 
highest compared to the other types of statins (Michael, 2005). 
